Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Minimal Residual Disease: Detection, Clinical Relevance, and Treatment Strategies
1996
Translocations of the RARα gene in acute promyelocytic leukemia
2001
ROS stress in cancer cells and therapeutic implications
2004 Standout
CNVnator: An approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing
2011
From traditional Chinese medicine to rational cancer therapy
2007 Standout
Retinoic acid receptors: From molecular mechanisms to cancer therapy
2014
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia
2003 Standout
Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
2012 Standout
Advances in metal-induced oxidative stress and human disease
2011 Standout
Acute and chronic arsenic toxicity
2003 Standout
Plumbagin induces ROS-mediated apoptosis in human promyelocytic leukemia cells in vivo
2009
Chemical and biological properties of toxic metals and use of chelating agents for the pharmacological treatment of metal poisoning
2010
Stressor-Induced Alteration of Cytokine Production in Multiple Sclerosis Patients and Controls
1998
Secondary cytogenetic changes in acute promyelocytic leukemia--prognostic importance in patients treated with chemotherapy alone and association with the intron 3 breakpoint of the PML gene: a Cancer and Leukemia Group B study.
1997
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
2009 Standout
A sensitive ELISPOT assay to detect low-frequency human T lymphocytes
1997
A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals
1999 StandoutNobel
Histone deacetylases and cancer: causes and therapies
2001 Standout
Hypoxia-HIF-1α-C/EBPα/Runx1 signaling in leukemic cell differentiation
2009
Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission
2001
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Polyoxometalate clusters, nanostructures and materials: From self assembly to designer materials and devices
2006 Standout
The VHL/HIF axis in clear cell renal carcinoma
2012 StandoutNobel
Checkpoint Blockade in Cancer Immunotherapy
2006 StandoutNobel
Heavy Metal Toxicity and the Environment
2012 Standout
Acute promyelocytic leukaemia: novel insights into the mechanisms of cure
2010
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry.
2004 Standout
Elevated serum levels of IFN-γ, IL-4 and TNF-α/unelevated serum levels of IL-10 in patients with demyelinating diseases during the acute stage
1998
Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129
2002
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
2012 Standout
Presentation of Epstein-Barr virus latency antigens to CD8+, interferon-γ-secreting, T lymphocytes
1999 StandoutNobel
In vivo Effects of a Histone Deacetylase Inhibitor, FK228, on Human Acute Promyelocytic Leukemia in NOD/Shi‐scid/scid Mice
2001
Identification of copy number variants in whole-genome data using Reference Coverage Profiles
2015 StandoutNobel
Association of PML-RAR alpha fusion mRNA type with pretreatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study.
1997
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Revised Recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia
2003 Standout
The Complex Role of Estrogens in Inflammation
2007 Standout
Anti-tumor, -viral, and -bacterial activities of polyoxometalates for realizing an inorganic drug
2005
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
2001 Standout
Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia
1999
Arsenic neurotoxicity — A review
2007
Structure of the STRA6 receptor for retinol uptake
2016 StandoutScienceNobel
Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
1999 StandoutNobel
IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis
2006 Standout
Bis- and Trisindolylmethanes (BIMs and TIMs)
2009 Standout
Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” Trial
1998
The Broad Scope of Health Effects from Chronic Arsenic Exposure: Update on a Worldwide Public Health Problem
2013 Standout
Three-dimensional organization of promyelocytic leukemia nuclear bodies
2010 StandoutNobel
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
2009 Standout
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
2003
Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
1999
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RARα Under Control of Cathepsin G Regulatory Sequences
1997
Bis-indols: a novel class of molecules enhancing the cytodifferentiating properties of retinoids in myeloid leukemia cells
2002
IMMUNOLOGY OF MULTIPLE SCLEROSIS
2005 Standout
Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid
1994
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
2005
The Effects of Cadmium Toxicity
2020 Standout
Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses
2005
T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis
1998
Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo
2001
Anti-CTLA-4 Antibody Treatment Triggers Determinant Spreading and Enhances Murine Myasthenia Gravis
2001
Protein Modification by SUMO
2004 Standout
Interleukin‐12 and Perforin mRNA Expression is Augmented in Blood Mononuclear Cells in Multiple Sclerosis
1998
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
1998 Standout
Prognostic significance of minimal residual disease detection and PML/RAR-α isoform type: long-term follow-up in acute promyelocytic leukemia
2001
Synergism between Arsenic Trioxide and Heat Shock Protein 90 Inhibitors on Signal Transducer and Activator of Transcription Protein 3 Activity—Pharmacodynamic Drug-Drug Interaction Modeling
2007
Deconstructing a Disease: RAR, Its Fusion Partners, and Their Roles in the Pathogenesis of Acute Promyelocytic Leukemia
1999
Perspectives on medicinal properties of plumbagin and its analogs
2010 Standout
Use of Arsenic Trioxide (As2O3 ) in the Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients
1997 Standout
Antigen-driven regulation of experimental autoimmune encephalomyelitis
1998
Works of ZY Wang being referenced
Establishment of a human acute promyelocytic leukemia-ascites model in SCID mice
1996
Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage
2001
Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse
1993
Acute promyelocytic leukemia: clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse
1993
Organ‐specific autoantigens induce interferon‐γ and interleukin‐4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis
1994